GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Current Ratio

Humacyte (Humacyte) Current Ratio

: 4.52 (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Humacyte's current ratio for the quarter that ended in Dec. 2023 was 4.52.

Humacyte has a current ratio of 4.52. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Humacyte's Current Ratio or its related term are showing as below:

HUMA' s Current Ratio Range Over the Past 10 Years
Min: 3.69   Med: 6.2   Max: 20.75
Current: 4.52

During the past 4 years, Humacyte's highest Current Ratio was 20.75. The lowest was 3.69. And the median was 6.20.

HUMA's Current Ratio is ranked better than
56.4% of 1555 companies
in the Biotechnology industry
Industry Median: 3.8 vs HUMA: 4.52

Humacyte Current Ratio Historical Data

The historical data trend for Humacyte's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Ratio
3.69 20.75 7.88 4.52

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.88 5.67 10.59 6.79 4.52

Competitive Comparison

For the Biotechnology subindustry, Humacyte's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Humacyte's Current Ratio distribution charts can be found below:

* The bar in red indicates where Humacyte's Current Ratio falls into.



Humacyte Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Humacyte's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=83.278/18.443
=4.52

Humacyte's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=83.278/18.443
=4.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humacyte  (NAS:HUMA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Humacyte Current Ratio Related Terms

Thank you for viewing the detailed overview of Humacyte's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte (Humacyte) Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente officer: Chief Regulatory Officer 90 DAVIS STREET, SEEKONK MA 02771
Todd Pope director C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713

Humacyte (Humacyte) Headlines